Rilpivirine

Drugs

Volumn 72, Issue 4, 2012, Pages 525-541

  Sanford, Mark ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Emtricitabinerilpivirine tenofovir disoproxil fumarate; HIV infections; Rilpivirine

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ANTACID AGENT; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; ETHINYLESTRADIOL; FAMOTIDINE; FUMARIC ACID; KETOCONAZOLE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; METHADONE; MOXIFLOXACIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NORETHISTERONE; OMEPRAZOLE; RILPIVIRINE; RITONAVIR; TENOFOVIR;

ANEMIA; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTICLE; BLOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CREATININE BLOOD LEVEL; DEPRESSION; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSOMNIA; LABORATORY TEST; LIPID BLOOD LEVEL; LYMPHATIC SYSTEM DISEASE; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; NIGHTMARE; NONHUMAN; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; TREATMENT RESPONSE;

ANTI-HIV AGENTS; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; NITRILES; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84857305890     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11208590-000000000-00000     Document Type: Article

References (35)

1. Joint United Nations Programme on HIV/AIDS. AIDS epidemic update [online]. Available from URL: http://www.unaids.org/en/media/unaids/ contentasssets/dataim port/pub/report/2009/jc1700-epi-update-2009-en.pdf [Accessed 2011 Oct 4].
2. Joint United Nations Programme on HIV/AIDS. Joint action for results-UNAIDS outcome framework: business case 2009-2011 [online]. Available from URL: http://www. unaids.org/en/media/unaids/contentassets/documents/un aidspublication/2010/20110101-JC1969-Treatment-ART.en. pdf [Accessed 2011 Oct 4]
3. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA Panel. JAMA 2010 Jul 21; 304 (3): 321-33
4. Panel on Antiretroviral Guideline for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services [online]. Available from URL: http://aidsinfo.gov/contentfiles/AdultandAdolescentGL.pdf [Accessed 2012 Jan 9]
5. Clumeck N, Pozniak A, Raffi F and the EACS Executive Committee. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIVinfected adults. HIV Med 2008 Feb; 9 (2): 65-71 (Pubitemid 351228129)
6. Gazzard BG. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. BHIVA Treatment Guidelines Writing Group. HIV Med 2008; 9 (8): 563-608
7. Adams J, Patel N, Mankaryous N, et al. Nonnucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents. Ann Pharmacother 2010 Jan; 44 (1): 157-65
8. Ghosn J, Chaix ML, Delaugerre C. HIV-1 resistance to firstand second-generation non-nucleoside reverse transcriptase inhibitors. AIDS Rev 2009; 11 (3): 165-73
9. Boehringer-Ingelheim. Viramune-(nevirapine tablets/oral suspension): US prescribing information [online]. Available from URL: http://www.accessdata.fda. gov/drugsatfda-docs/label/2011/020636s039-020933s030lbl.pdf [Accessed 2011 Dec 9]
10. Deeks ED, Keating GM. Etravirine. Drugs 2008; 68 (16): 2357-72
11. Tibotec Pharmaceuticals. Edurant-(rilpivirine) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/202022s000lbl.pdf [Accessed 2011 Sep 26]
12. European Medicines Agency. Edurant-25 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002264/WC500118874. pdf [Accessed2011 Dec 9]
13. Lewis W, Day BJ, Copeland WC. Mitochondrial toxicity of NRTI antiviral drugs: an integrated cellular perspective. Nat Rev Drug Discov 2003 Oct; 2 (10): 812-22 (Pubitemid 37361813)
14. AzijnH, Tirry I,Vingerhoets J, et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010 Feb; 54 (2): 718-27
15. Goebel F, Yakovlev A, Pozniak AL, et al. Short-term antiviral activity of TMC278, a novel NNRTI, in treatmentnaive HIV-1-infected subjects. AIDS 2006 Aug 22; 20 (13): 1721-6 (Pubitemid 44299363)
16. Rimsky L, Vingerhoets J, Van Eygen V, et al. Genotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysis. J Acquir Immune Defic Syndr 2012 Jan 1; 59 (1): 39-46
17. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. AIDS 2010 Jan 2; 24 (1): 55-65
18. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatmentnaive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011 Jul 16; 378 (9787): 238-46
19. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011 Jul 16; 378 (9787): 229-37
20. Crauwels HM, van Schaik E, van Heeswijk RPG, et al. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral naive, HIV-1-infected patients in ECHO and THRIVE [abstract no. P186]. 10th International Congress on Drug Therapy in HIV Infection; 2010 Nov 7-11; Glasgow
21. Lachau-Durand S, Mamidi RNVS, Cuyckens F, et al. Absorption, metabolism and excretion of TMC278, a nextgeneration non-nucleoside reverse transcriptase inhibitor (NNRTI), after a single oral dose of 150 mg in healthy male volunteers [abstract no. PE7.1/3]. 12th European AIDS Conference; 2009 Nov 11-14; Cologne
22. Crauwels H, van Heeswijk R, Cornelis L, et al. Pharmacokinetic interaction study between TMC278, a nextgeneration nonnucleoside reverse transcriptase inhibitor (NNRTI), and the contraceptives norethindrone plus ethinylestradiol [abstract no. PE4.3/3]. 12th European AIDS Conference; 2009 Nov 11-14; Cologne
23. Crauwels H, van Heeswijk R, Vandevoorde A, et al. Pharmacokinetic interaction study between TMC278, a nextgeneration non-nucleoside reverse transcriptase inhibitor, and methadone [abstract no. WEPE0089]. 18th International AIDS Conference; 2010 Jul 18-23; Vienna
24. Crauwels HM, van Heeswijk RPG, Kestens D, et al. The pharmacokinetic interaction between omeprazole and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor [abstract P239]. J Int AIDS Soc 2008 Nov 10; 11 Suppl. 1
25. Mathias A, Menning M, Wei X, et al. Bioequivalence of the co-formulation of emtricitabine/rilpivirine/tenofovir DF [abstract no. LBPE17]. 18th International AIDS Conference; 2010 Jul 18-23; Vienna
26. van't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010 May; 54 (5): 2042-50
27. Cohen C, Molina J-M, Cassetti I, et al. Pooled week 96 efficacy, resistance and safety results from the doubleblind, randomised, phase III trials comparing rilpivirine (RPV) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults [abstract no. TULBPE032]. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; 2011 Jul 17-20; Rome
28. Brochot A, Vis P, Corbett C, et al. Generalized additive modelling of virologic response to the NNRTIs rilpivirine (RPV, TMC278) and efavirenz (EFV) in treatment-naive HIV-infected patients: pooled week 48 data from ECHO and THRIVE [abstract plus poster no. PS12/7]. 13th European AIDS Conference; 2011 Oct 12-15; Belgrade
29. Wilkin A, Pozniak AL, Morales-Ramirez J, et al. TMC278 shows favorable tolerability and non-inferior efficacy compared to efavirenz over 192 weeks in HIV-1-infected treatment-naive patients [abstract]. 2nd Italian Conference on AIDS and Retroviruses; 2010 Jun 20-22; Brescia
30. Nelson M, Amaya G, Clumeck N, et al. Efficacy and safety of TMC278 in treatment-naive, HIV-1-infected patients with HBV/HCV coinfection enrolled in the phase III ECHO and THRIVE trials [abstract no. P210]. 10th International Congress on Drug Therapy in HIV Infection; 2010 Nov 7-11; Glasgow
31. Wohl D, Doroana M, Orkin C, et al. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the phase III ECHO trial [abstract no. O-1014]. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston (MA)
32. Rashbaum B, Girard P, Rachlis A, et al. Rilpivirine (RPV, TMC278) tolerability over the first 12 weeks of treatment in the phase 3 ECHO and THRIVE studies [abstract no. H2-805]. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2011 Sep 17-20; Chicago (IL)
33. Mills A, Antinori A, Clotet B, et al. Neurologic and psychiatric safety profile of TMC278 compared with EFV in treatment-naive HIV-1+ patients: ECHO and THRIVE trials at 48 weeks [abstract no. 420]. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston (MA)
34. Arribas J, Andrade-Villanueva J, Bellos N, et al. Lipid profiles of TMC278 and EFV in treatment-naive HIV-1+ patients: pooled week-48 data from the randomized double-blind phase III ECHO and THRIVE trials [abstract no. 819]. 18th Conference on Retroviruses and Opportunistic Infections; 2011 Feb 27-Mar 2; Boston (MA)
35. Vanveggel S, Buelens A, Crauwels H, et al. TMC278 25mg qd has no effect on correctedQT (QTC) interval inHIV-negative volunteers [abstract no. 285]. 47th Annual Meeting of the Infectious Diseases Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)